Gold prices steady ahead of Fed decision; weekly weakness noted
Tuesday, LENZ Therapeutics Inc (NASDAQ:LENZ), currently trading at $25.28, received continued support from Citi, as the firm reiterated its Buy rating and $44.00 price target for the company’s stock. The target aligns with the broader analyst consensus, which ranges from $36 to $45. Citi’s endorsement follows a European non-deal roadshow (NDR), where management met with potential investors in Frankfurt, Zurich, and London. InvestingPro data shows the stock has delivered an impressive 55.68% return over the past year. The analyst highlighted LENZ Therapeutics’ focus on developing a presbyopia eye drop, LNZ100, which is anticipated to significantly change the treatment paradigm for age-related loss of near vision.
The analyst emphasized the drug’s unique mechanism of action (MoA) that selectively targets the pupil, and noted the successful completion of Phase 3 trials that demonstrated what is considered best-in-class efficacy and safety. These results support the company’s claims of having overcome clinical and trial risks, as detailed in Citi’s initiation report. According to InvestingPro analysis, LENZ maintains a strong financial health score of GOOD, with more cash than debt on its balance sheet, positioning it well for the drug’s potential launch.
Furthermore, the analyst pointed out the limited regulatory risk for LNZ100, with a Prescription Drug User Fee Act (PDUFA) date set for August 8, 2025. The positive outcome of a recent mid-cycle meeting with regulators was seen as a strong indicator of the drug’s potential for approval. Citi models a high probability of success (PoS) at approximately 95% for LNZ100’s market authorization.
In summary, Citi’s analysis suggests that LENZ Therapeutics is well-positioned to succeed with its presbyopia treatment, backed by strong clinical data and a favorable regulatory outlook. The firm’s reiterated Buy rating and $44.00 price target reflect confidence in the company’s ability to execute its strategy and deliver on its promises to stakeholders. While the company currently operates at a loss with an EBITDA of -$68.34M, its robust current ratio of 28.63 suggests strong liquidity. Subscribers to InvestingPro can access 6 additional investment tips and comprehensive financial metrics to better evaluate LENZ’s investment potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.